Clinical Trial Update: An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain [Phase 3]

View source ↗

Summary

An open-label extension study of extended-release tapentadol (CG5503) in adults with moderate to severe chronic pain completed Phase 3 with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low Back Pain
• Osteoarthritis
• Pain

Drugs mentioned

• Tapentadol ER (CG5503) (tapentadol)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Pain, Osteoarthritis | Phase 3 | Status: COMPLETED | Results posted: 2010-07-23